Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JVS-100 in Ischemic Heart Failure
NCT01643590Phase 2Unknown
- Sponsor
- Juventas Therapeutics
- Start
- Jul 2012
- Primary completion
- Oct 2014
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 2 trial of JVS-100 in ischemic heart failure (IHF), sponsored by Juventas Therapeutics. Status: unknown.
02
Drugs
JVS-100
03
Conditions
ischemic heart failure (IHF)
Beyond the preview
Go deeper on NCT01643590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01643590.